- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Outreach
- Careers
- About
- For Pain Patients and Professionals
Papers: 29 Apr 2023 - 5 May 2023
RESEARCH TYPE:
Clinical
Human Studies, Molecular/Cellular, Neurobiology
PAIN TYPE:
Inflammation/Inflammatory, Psychological/Comorbidities
2023 May
EClinicalMedicine
59
Vitamin D insufficiency is associated with risk of multiple sclerosis (MS) relapse; whether supplementation influences prognosis is unknown. The Vitamin D to Ameliorate MS (VIDAMS) trial aimed to determine if high dose (5000 International Units (IU)/day) versus low dose (600 IU/day) vitamin D added to daily glatiramer acetate (GA), reduced the risk of clinical relapse in people with established relapsing remitting MS (RRMS) over 96 weeks.